Emerging strategies with early in vitro data from cervical cancer cell lines include the prevention of downstream tumor suppressor degradation via targeted disruption of viral oncoprotein binding (e.g., between E6/p53 or E7/PTPN14) and targeted HPV oncoprotein degradation via proteolysis-targeting chimera (PROTAC) technology [138,139,140,141]. This evidence concerns the gene TP53 and cervical cancer.